Immunotherapies for COVID-19: lessons learned from sepsis-Reference-Cited by-同舟云学术

Immunotherapies for COVID-19: lessons learned from sepsis

Published:2020-10 Issue:10 Volume:8 Page:946-949
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Remy Kenneth E,Brakenridge Scott C,Francois Bruno,Daix Thomas,Deutschman Clifford S,Monneret Guillaume,Jeannet Robin,Laterre Pierre-Francois,Hotchkiss Richard S,Moldawer Lyle L

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference22 articles.

1. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome;Kotch;Expert Rev Clin Immunol,2019

2. FDA Approval Summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome;Le;Oncologist,2018

3. Cytokine storm and sepsis disease pathogenesis;Chousterman;Semin Immunopathol,2017

4. Failure of treatments based on the cytokine storm theory of sepsis: time for a novel approach;Giamarellos-Bourboulis;Immunotherapy,2013

5. Tocilizumab treatment in COVID-19: a single center experience;Luo;J Med Virol,2020

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Determining potential immunomodulatory drug efficacy in sepsis using ELISpot;2024-07-16

2. Exploring the relationship between HCMV serostatus and outcomes in COVID-19 sepsis;Frontiers in Immunology;2024-05-08

3. Bioinformatics-based analysis of the dialog between COVID-19 and RSA;Heliyon;2024-05

4. Quantum Defect Sensitization via Phase-Changing Supercharged Antibody Fragments;Journal of the American Chemical Society;2024-04-30

5. Along with PaO2/FiO2 ratio and lymphopenia, low HLA-DR monocytes are the only additional parameter that independently predicts the clinical course of undifferentiated SARS-CoV-2 patients in emergency departments;Journal of Leukocyte Biology;2024-02-15